Incyte Corporation (INCY)
Market Closed
22 Jul, 20:00
$
115. 79
-1.6
-1.363%
$
22.99B Market Cap
33.14 P/E Ratio
- Div Yield
998,332 Volume
3.57 Eps
$ 117.39
Previous Close 
Want to track INCY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024
Cathie Wood was the hottest money manager in the game in 2020. Her Ark Invest family of funds offered investors blistering returns on their money.
Investorplace | 2 years ago
Incyte: The Worst Has Been Avoided
In recent months, Incyte's management has continued to delight investors by accelerating the pace of development of its anti-inflammatory treatments. On May 30, 2024, Incyte announced the completion of its acquisition of Escient Pharmaceuticals for $750 million. Sales of Opzelura, one of the company's gems, totaled $85.7 million in the first quarter of 2024, up 51.4% year-on-year.
Seekingalpha | 2 years ago
Incyte (INCY) Up 7.5% Since Last Earnings Report: Can It Continue?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Zacks | 2 years ago
Here's Why Incyte (INCY) Stock is Up More Than 7% in a Week
Incyte (INCY) rises 7% in a week as investors appreciated the company's buyback plan to boost returns.
Zacks | 2 years ago
